Ask AI
Modern Management of PNH
Paroxysmal Nocturnal Hemoglobinuria: Translating Pathobiology Into Modern Clinical Management

Released: October 28, 2025

Activity

Progress
1
Course Completed

In this educational podcast discussion, Carlos M. De Castro, MD, and David Dingli, MD, PhD, FRCP, FRCPEd, FACP, FRCPath, explore paroxysmal nocturnal hemoglobinuria (PNH). They trace the evolution of treatment from early complement inhibitors to today’s expanding therapeutic options, emphasizing how these advances have transformed patient outcomes and quality of life. The conversation blends clinical insights with practical considerations for therapy selection and patient care, including:

  • The pathogenesis of PNH and the role of complement activation
  • Landmark therapies such as eculizumab and ravulizumab
  • Advances in proximal inhibitors (eg, pegcetacoplan, iptacopan, danicopan)
  • Quality-of-life considerations, treatment personalization, and emerging therapies